AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer

 AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and MSD Reports Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer

Shots:

  • The P-III GY004 study involves assessing of cediranib + Lynparza vs Lynparza as monothx. vs standard platinum-based CT in patients with recurrent platinum-sensitive OC, fallopian tube, or primary peritoneal cancer patients, with/without a BRCA mutation
  • The P-III GY004 study resulted in not meeting its 1EPs in IIT population i.e. an improvement in PFS when cediranib added to Lynparza, safety & tolerability profile is consistent with the known profile of individual therapy
  •  Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation). Cediranib is an oral VEGFR inhibitor, targeting the growth of blood vessels supporting tumor growth

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Livemint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post